8H08

SARS-CoV-2 BA.1 variants S ectodomain trimer in complex with neutralizing antibody 10-5B and 6-2C

Summary for 8H08

• Entry DOI: 10.2210/pdb8h08/pdb
• EMDB information: 34411
• Descriptor: Spike glycoprotein, 10-5B H chain, 10-5B L chain, ... (6 entities in total)
• Functional Keywords: sars-cov-2 ba.1, antibody, virus, viral protein-immune system complex, viral protein/immune system
• Biological source: Severe acute respiratory syndrome coronavirus 2; More
• Total number of polymer chains: 15
• Total formula weight: 581793.70

Authors

Wang, X.,Wang, Z. (deposition date: 2022-09-28, release date: 2023-05-31, Last modification date: 2024-10-16)

Primary citation

Liu, Y.,Wang, Z.,Zhuang, X.,Zhang, S.,Chen, Z.,Zou, Y.,Sheng, J.,Li, T.,Tai, W.,Yu, J.,Wang, Y.,Zhang, Z.,Chen, Y.,Tong, L.,Yu, X.,Wu, L.,Chen, D.,Zhang, R.,Jin, N.,Shen, W.,Zhao, J.,Tian, M.,Wang, X.,Cheng, G.
Inactivated vaccine-elicited potent antibodies can broadly neutralize SARS-CoV-2 circulating variants.
Nat Commun, 14:2179-2179, 2023

PubMed Abstract: A full understanding of the inactivated COVID-19 vaccine-mediated antibody responses to SARS-CoV-2 circulating variants will inform vaccine effectiveness and vaccination development strategies. Here, we offer insights into the inactivated vaccine-induced antibody responses after prime-boost vaccination at both the polyclonal and monoclonal levels. We characterized the VDJ sequence of 118 monoclonal antibodies (mAbs) and found that 20 neutralizing mAbs showed varied potency and breadth against a range of variants including XBB.1.5, BQ.1.1, and BN.1. Bispecific antibodies (bsAbs) based on nonoverlapping mAbs exhibited enhanced neutralizing potency and breadth against the most antibody-evasive strains, such as XBB.1.5, BQ.1.1, and BN.1. The passive transfer of mAbs or their bsAb effectively protected female hACE2 transgenic mice from challenge with an infectious Delta or Omicron BA.2 variant. The neutralization mechanisms of these antibodies were determined by structural characterization. Overall, a broad spectrum of potent and distinct neutralizing antibodies can be induced in individuals immunized with the SARS-CoV-2 inactivated vaccine BBIBP-CorV, suggesting the application potential of inactivated vaccines and these antibodies for preventing infection by SARS-CoV-2 circulating variants.

PubMed: 37069158
DOI: 10.1038/s41467-023-37926-7

Experimental method

ELECTRON MICROSCOPY (3.2 Å)